Bioanalytical Testing Services for Vaccine Components

A bioanalytical laboratory develops, validates, and performs assays to measure drugs, biologics, and biomarkers in biological matrices. For vaccines, labs quantify antigens, assess adjuvants, evaluate immune responses, and characterize impurities or degradation products, generating data packages and reports that support preclinical decision-making and regulatory submissions.

There is no single gold standard. Robust vaccine testing uses orthogonal methods: immunogenicity (e.g., binding and neutralization assays), potency assays, purity and identity testing (HPLC/LC–MS), and safety-related assays (endotoxin, bioburden). Method selection follows FDA/ICH guidance, pharmacopeial standards, and program-specific risk assessments.

Key components include study design and endpoints, material sourcing and controls, assay development and validation, sample collection and handling, routine analysis with QC, data review, and reporting. For vaccines, this spans immunogenicity, potency, stability, and impurity testing, with documentation aligned to regulatory expectations.

Typical assays include ELISA for antigen/antibody quantitation, neutralization assays for functional response, HPLC/LC–MS for purity and impurities, endotoxin testing, and particle or size analysis where relevant. Orthogonal methods are combined to confirm identity, potency, stability, and overall quality of vaccine components.

Timelines vary by method complexity and sample volume. As a guide, feasibility and development may take 2–6 weeks, validation 3–6 weeks, and routine sample analysis 1–3 weeks per batch. Early alignment on assay scope, acceptance criteria, and reporting needs helps compress overall timelines.

Yes. We perform phase-appropriate validation aligned with FDA/ICH bioanalytical method validation guidance, assessing accuracy, precision, selectivity, stability, and robustness. Documentation includes protocols, validation summaries, and QC plans to support reliable preclinical decision-making and submissions.

Common matrices include serum, plasma, whole blood, and tissue homogenates, plus buffers for component characterization. We assess matrix effects during development to establish suitable dynamic ranges, recovery, and selectivity, ensuring methods perform reliably in the intended study matrix.

We implement controlled sample receipt, barcoding, temperature monitoring, and audit trails. Blinded runs, calibration standards, QC samples, and documented reviews support data integrity. Traceable chain-of-custody records and secure storage protect sample identity and maintain compliance-ready documentation.